Shares of Bullfrog AI Holdings (NASDAQ: BFRG) soared nearly 26% on Friday following the revelation of preliminary findings from its partnership with the Lieber Institute for Brain Development (LIBD).
Bullfrog AI Holdings (NASDAQ: BFRG) announced preliminary results from its partnership with the Lieber Institute for Brain Development (LIBD). The results could potentially transform the way psychiatric disorders are understood and treated.
The initial outcomes of this global strategic alliance have successfully categorized brain expression data, potentially providing unparalleled insights into psychiatric conditions.
Vin Singh, BullFrog AI’s CEO, stated,
“This partnership signifies a crucial juncture in psychiatric research.”
“Our bfLEAP™ platform’s application to LIBD’s unmatched brain data has allowed us to make substantial progress in deciphering the biological foundations of psychiatric disorders. These initial findings could not only enhance our comprehension but also lay the groundwork for the creation of more specific and effective treatments, setting us up to pursue strategic partnerships with pharmaceutical companies that generate revenue.”
The exclusive data from LIBD comprised gene expression data from over 2,800 brain samples, including schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. For the first time, BullFrog AI and LIBD have grouped subjects based on their biological data alone, disregarding their behavioral diagnoses. This novel method has yielded encouraging insights, underlining distinct differences and similarities in biological pathways across various brain disorders. Furthermore, it has uncovered biological subtypes within individual disorders, providing a detailed understanding that could lead to personalized treatment strategies.
Daniel R. Weinberger, M.D., Director and CEO of LIBD, commented,
“Our partnership with BullFrog AI has allowed us to apply state-of-the-art AI technologies to our extensive brain data. The preliminary results are intriguing and offer unique insights at the gene level that may only be discoverable using these innovative AI technologies, providing a fresh perspective through which we can observe and potentially treat brain disorders. This is a significant initial step towards personalized medicine in psychiatry.”
The agreement between the two organizations, announced in September 2023, gave BullFrog AI exclusive access to LIBD’s brain data, with the possibility of commercializing products or services resulting from the collaboration.
As of the close of trading on Friday, BFRG stock was up 25.70%, with 37.43 million shares traded. This figure exceeds the company’s daily average trading volume of 1.19 million shares.